Skip to main content

European Union’s Clinical Trials Directive

BayBiotech.NET
Following is a summary of the key points on the laws, regulations and Good Clinical Practices of the Member States as per European Union’s Directive for conduct of Clinical Trials on human subjects:

1. Directive requires that applications for authorization to place a medicinal product on the market should be accompanied by a dossier containing particulars and documents relating to the results of tests and clinical trials carried out on the product. A dossier must be prepared in compliance with uniform rules laid down by the Member States.

2. A detailed risk assessment and management strategy must be in place based on the toxicological data derived at Pre-clinical research stage.

3. Persons who are incapable of giving legal consent such as dementia, psychiatric patients etc. to clinical trials should be given special protection. Such persons may not be included in clinical trials if the same results can be obtained using persons capable of giving consent. These persons should be included in clinical trials only when there are grounds for expecting that the administering of the medicinal product would be of direct benefit to the patient. However, if possible clinical trials must involve children in order to evolve better treatments for them.

4. In order to achieve optimum protection of health, obsolete or repetitive tests will not be carried out, whether within the Community or in third countries. Such initiatives must be conducted through the International Conference on Harmonization.

5. For Medicinal Products intended for gene therapy or cell therapy, prior scientific evaluation by the European Agency for the Evaluation of Medicinal Products assisted by the Committee for Proprietary Medicinal Products, is mandatory before the Commission grants marketing authorization.

6. Information on the content, commencement and termination of a clinical trial should be available to the Member State where the trial takes place and all the other Member States should have access to the same information.

7. As a rule, if there has been a vote in favor by the Ethics Committee and the competent authority has not objected within a given period, it should be possible to begin the clinical trials. In exceptional cases especially for complex problems/ treatments, explicit written authorization should be obtained.

8. The principles of good manufacturing practice should be applied to investigational medicinal products and for the labeling of these products.

9. The person participating in a trial must consent to the scrutiny of personal information during inspection by competent authorities and properly authorized persons, provided that such personal information is treated as strictly confidential and is not made publicly available.


10. It is also necessary to make provision for the monitoring of adverse reactions occurring in clinical trials using Community surveillance (pharmacovigilance) procedures.


Thus, this provides a snapshot of the key elements of EU’s Clinical Trials Directive. The information provided here is extracted from Official Journal of the European Communities (1.5.2001): L 121/34- 44.

Comments

Popular posts from this blog

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...

Food Safety Bill: A major overhaul of the Food Safety System

BayBiotech.NET The recently passed Food Safety bill is being considered to be a major overhaul of the food safety system in the United States and is considered to change the mission of the FDA, focusing it on preventing food-borne illnesses rather than reacting after an outbreak occurs. Under this legislation, food manufacturers are required to examine their processing systems to identify possible ways that food products can become contaminated and to develop detailed plans to keep that from happening. Companies must share those plans with the F.D.A., and provide the agency with records, including product test results, showing how effectively they carry them out. To read more about it follow the link